Browsing Tag
Hepcludex
3 posts
How a first-in-class HDV approval could support Gilead Sciences’ long-term antiviral portfolio
Find out how Hepcludex approval could strengthen Gilead Sciences’ antiviral portfolio and reshape HDV care in the U.S.
How confirmatory trial pressure could shape the future of HDV treatment markets
FDA approval gave Hepcludex a major HDV breakthrough, but confirmatory trials may decide its long-term future. Read the full analysis.
Gilead Sciences acquisition of MYR: A strategic move to tackle hepatitis delta virus
In a strategic acquisition aimed at expanding its hepatitis treatment portfolio, US biopharmaceutical giant Gilead Sciences has announced…